Robaxin label

Robaxin

Robaxin Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Since methocarbamol may possess a general CNS depressant effect, patients receiving robaxin® or robaxin®-750 should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of robaxin® and robaxin®-750 has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, robaxin® and robaxin®-750 should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy).

Use In Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

robaxin® and robaxin®-750 are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

History

There is currently no drug history available for this drug.

Other Information

robaxin®/robaxin®-750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C11H15NO5. Its molecular weight is 241.24. The structural formula is shown below.

Chemical Structure

Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

robaxin® is available as a light orange, round, film-coated tablet containing 500 mg of methocarbamol, USP for oral administration. The inactive ingredients present are corn starch, FD&C Yellow 6, hydroxypropyl cellulose, hypromellose, magnesium stearate, polysorbate 20, povidone, propylene glycol, saccharin sodium, sodium lauryl sulfate, sodium starch glycolate, stearic acid, titanium dioxide.

robaxin®-750 is available as an orange capsule-shaped, film-coated tablet containing 750 mg of methocarbamol, USP for oral administration. In addition to the inactive ingredients present in robaxin®, robaxin®-750 also contains D&C Yellow 10.

Robaxin Manufacturers

  • Schwarz Pharma Inc.
    Robaxin | Schwarz Pharma Inc.
    No Recall

    Robaxin | Schwarz Pharma Inc.

    Robaxin | Schwarz Pharma Inc.

    robaxin® (methocarbamol), 500 mg – Adults:
    Initial dosage: 3 tablets q.i.d.
    Maintenance dosage: 2 tablets q.i.d.
    robaxin®-750 (methocarbamol): 750 mg – Adults:
    Initial dosage: 2 tablets q.i.d.
    Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

    Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

  • Stat Rx Usa Llc
    Robaxin | Stat Rx Usa Llc
    No Recall

    Robaxin | Stat Rx Usa Llc

    Robaxin | Stat Rx Usa Llc

    There is currently no dosage information available for this product. We apologize for any inconvenience.

  • Pd-rx Pharmaceuticals, Inc.
    Robaxin | Pd-rx Pharmaceuticals, Inc.
    No Recall

    Robaxin | Pd-rx Pharmaceuticals, Inc.

    Robaxin | Pd-rx Pharmaceuticals, Inc.

    robaxin® (methocarbamol), 500 mg – Adults:
    Initial dosage: 3 tablets q.i.d.
    Maintenance dosage: 2 tablets q.i.d.
    robaxin®-750 (methocarbamol): 750 mg – Adults:
    Initial dosage: 2 tablets q.i.d.
    Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

    Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

  • Actient Pharmaceuticals, Llc
    Robaxin | Actient Pharmaceuticals, Llc
    No Recall

    Robaxin | Actient Pharmaceuticals, Llc

    Robaxin | Actient Pharmaceuticals, Llc

    robaxin® (methocarbamol), 500 mg – Adults:
    Initial dosage: 3 tablets q.i.d.
    Maintenance dosage: 2 tablets q.i.d.
    robaxin®-750 (methocarbamol): 750 mg – Adults:
    Initial dosage: 2 tablets q.i.d.
    Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

    Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

  • West-ward Pharmaceutical Corp.
    Robaxin | West-ward Pharmaceutical Corp.
    No Recall

    Robaxin | West-ward Pharmaceutical Corp.

    Robaxin | West-ward Pharmaceutical Corp.

    For Intravenous and Intramuscular Use Only. Total adult dosage should not exceed 30 mL (3 vials) a day for more than 3 consecutive days except in the treatment of tetanus. If the condition persists, a like course may be repeated after a drug-free interval of 48 hours. Dosage and frequency of injection should be based on the severity of the condition being treated and therapeutic response noted.

    For the relief of symptoms of moderate degree, one dose of 1 gram (one 10 mL vial) may be adequate. Ordinarily this injection need not be repeated, as the administration of the oral form will usually sustain the relief initiated by the injection. For the severest cases or in postoperative conditions in which oral administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.

    Directions for Intravenous Use

    ROBAXIN Injectable may be administered undiluted directly into the vein at a maximum rate of three mL per minute. It may also be added to an intravenous drip of Sodium Chloride Injection (Sterile Isotonic Sodium Chloride Solution for Parenteral Use) or five percent Dextrose Injection (Sterile 5 percent Dextrose Solution); one vial given as a single dose should not be diluted to more than 250 mL for I.V. infusion. AFTER MIXING WITH I.V. INFUSION FLUIDS, DO NOT REFRIGERATE. Care should be exercised to avoid vascular extravasation of this hypertonic solution, which may result in thrombophlebitis. It is preferable that the patient be in a recumbent position during and for at least 10 to 15 minutes following the injection.

    Directions for Intramuscular Use

    When the intramuscular route is indicated, not more than five mL (one-half vial) should be injected into each gluteal region. The injections may be repeated at eight hour intervals, if necessary. When satisfactory relief of symptoms is achieved, it can usually be maintained with tablets.

    Not Recommended for Subcutaneous Administration.

    Special Directions for Use in Tetanus

    There is clinical evidence which suggests that methocarbamol may have a beneficial effect in the control of the neuromuscular manifestations of tetanus. It does not, however, replace the usual procedure of debridement, tetanus antitoxin, penicillin, tracheotomy, attention to fluid balance, and supportive care. ROBAXIN Injectable should be added to the regimen as soon as possible.

    For adults: Inject one or two vials directly into the tubing of the previously inserted indwelling needle. An additional 10 mL or 20 mL may be added to the infusion bottle so that a total of up to 30 mL (three vials) is given as the initial dose (see PRECAUTIONS). This procedure should be repeated every six hours until conditions allow for the insertion of a nasogastric tube. Crushed methocarbamol tablets suspended in water or saline may then be given through this tube. Total daily oral doses up to 24 grams may be required as judged by patient response.
    For pediatric patients: A minimum initial dose of 15 mg/kg or 500 mg/m2 is recommended. This dosage may be repeated every six hours, if required. The total dose should not exceed 1.8 g/m2 for 3 consecutive days. The maintenance dosage may be given by injection into tubing or by I.V. infusion with an appropriate quantity of fluid. See directions for I.V. use.

  • Remedyrepack Inc.
    Robaxin | Remedyrepack Inc.
    No Recall

    Robaxin | Remedyrepack Inc.

    Robaxin | Remedyrepack Inc.
    robaxin(methocarbamol), 500 mgAdults:
    Initial dosage: 3 tablets q.i.d.
    Maintenance dosage: 2 tablets q.i.d.
    robaxin(methocarbamol): 750 mgAdults:
    Initial dosage: 2 tablets q.i.d.
    Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.
    Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.